SCHEMBL4119044

SCHEMBL4119044

CCOC(=O)c1ccc(NC(=O)Nc2ccc(OC(C)C)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.66
MEN1 O00255 5/20 0.66
KMT2A Q03164 5/20 0.66
TRPV1 Q8NER1 2/20 0.66
CASP3 P42574 1/20 0.66
SENP7 Q9BQF6 1/20 0.66
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
CA9 Q16790 1/20 0.64
ALDH1A1 P00352 2/20 0.59
MAPK1 P28482 1/20 0.59
GAA P10253 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
RAB9A P51151 4/20 0.58
NPC1 O15118 3/20 0.58
NAMPT P43490 2/20 0.57
TSHR P16473 1/20 0.56
TP53 P04637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4107148 0.89 TRPV1 (0.68) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL982169 0.88 CA12 (0.59) MAPTKMT2ACA12CA1CA2
SCHEMBL4112564 0.88 MEN1 (0.68) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4105862 0.87 RAB9A (0.76) MAPTMEN1KMT2ATRPV1CA12
SCHEMBL4112717 0.84 MAPT (0.76) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4127544 0.84 MEN1 (0.78) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4110188 0.83 MEN1 (0.69) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4923105 0.83 MAPT (0.69) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4105749 0.83 MAPT (0.61) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4113517 0.82 GLA (0.59) MAPTMEN1KMT2AALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MAPT 1654/4885MEN1 3273/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.